Refoxy Pharmaceuticals Raises €9.1 Million To Progress Its Novel FOXO3 Therapeutics For Idiopathic Pulmonary Fibrosis

(MENAFN - EIN Presswire) Investment led by Boehringer Ingelheim Venture Fund, with the participation of new & existing investors, including Apollo Health Ventures, NRW, & HTGF.COLOGNE, GERMANY, ...

By: menafn